CARVYKTI® is the first CAR-T therapy for patients with relapsed and refractory multiple myeloma to receive a positive CHMP opinion for second line treatment
.
Massachusetts Financial Services Co. MA lifted its position in shares of Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 12.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,867,032 shares of the company’s stock after buying an additional 212,327 shares during the quarter. Massachusetts […]
Legend Biotech Co (NASDAQ:LEGN) Receives $82 41 Average Price Target from Brokerages theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Jump Financial LLC raised its holdings in Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 2.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 47,209 shares of the company’s stock after purchasing an additional 1,274 shares during the quarter. Jump Financial LLC’s holdings […]
Legend Biotech (NASDAQ:LEGN – Free Report) had its price objective increased by Barclays from $93.00 to $94.00 in a research report report published on Wednesday morning, Benzinga reports. The firm currently has an overweight rating on the stock. Several other research firms have also weighed in on LEGN. The Goldman Sachs Group started coverage on […]